Differential regulation of mesodermal gene expression by Drosophila cell type-specific Forkhead transcription factors

Xianmin Zhu¹, Shaad M. Ahmad¹, Anton Aboukhalil², Brian W. Busser¹, Yongsok Kim¹, Terese R. Tansey¹, Adrian Haimovich¹, Neal Jeffries⁴, Martha L. Bulyk²,³,⁵ and Alan M. Michelson¹,‡

SUMMARY
A common theme in developmental biology is the repeated use of the same gene in diverse spatial and temporal domains, a process that generally involves transcriptional regulation mediated by multiple separate enhancers, each with its own arrangement of transcription factor (TF)-binding sites and associated activities. Here, by contrast, we show that the expression of the Drosophila Nidogen (Ndg) gene at different embryonic stages and in four mesodermal cell types is governed by the binding of multiple cell-specific Forkhead (Fkh) TFs – including Biniou (Bin), Checkpoint suppressor homologue (CHES-1-like) and Jumeau (Jumu) – to three functionally distinguishable Fkh-binding sites in the same enhancer. Whereas Bin activates the Ndg enhancer in the late visceral musculature, CHES-1-like cooperates with Jumu to repress this enhancer in the heart. CHES-1-like also represses the Ndg enhancer in a subset of somatic myoblasts prior to their fusion to form multinucleated myotubes. Moreover, different combinations of Fkh sites, corresponding to two different sequence specificities, mediate the particular functions of each TF. A genome-wide scan for the occurrence of both classes of Fkh domain recognition sites in association with binding sites for known cardiac TFs showed an enrichment of combinations containing the two Fkh motifs in putative enhancers found within the noncoding regions of genes having heart expression. Collectively, our results establish that different cell-specific members of a TF family regulate the activity of a single enhancer in distinct spatiotemporal domains, and demonstrate how individual binding motifs for a TF class can differentially influence gene expression.

KEY WORDS: Transcription factors, Transcription factor binding sites, Forkhead proteins, Transcriptional regulation, Enhancers, Mesoderm

INTRODUCTION
The Drosophila embryonic mesoderm gives rise to multiple tissues and organs in the larva and adult fly, including the heart, the gut musculature, the somatic muscles, fat body and hemocytes. The developmental processes associated with the formation of these derivatives require the coordinated regulation of a diverse array of genes in precise spatial and temporal expression patterns (Frasch, 1999; Tao and Schulz, 2007; Bonn and Furlong, 2008; Busser et al., 2008; Tixier et al., 2010). Previous work has shown that gene expression in subsets of Drosophila embryonic mesodermal cells involves the binding of multiple signal-activated, tissue- and cell-specific transcription factors (TFs) to transcriptional enhancers that integrate these intrinsic and extrinsic combinatorial inputs (Xu et al., 1998; Halfon et al., 2000; Lee and Frasch, 2005; Estrada et al., 2006; Philippakis et al., 2006).

Although the identities of some of the TFs and binding sites that comprise several model mesodermal enhancers have been described (Gajewski et al., 1997; Cripps et al., 1998; Gajewski et al., 1998; Xu et al., 1998; Kremser et al., 1999; Halfon et al., 2000; Gajewski et al., 2001; Knirr and Frasch, 2001; Han et al., 2002; Lee and Frasch, 2005; Wang et al., 2005; Estrada et al., 2006; Philippakis et al., 2006; Tao et al., 2007), the transcriptional codes that are currently known cannot account for the complete specificity of target gene expression at the resolution of single cells. Thus, the challenge is both to expand and refine these transcriptional codes by examining the functions of other TFs that participate in individual regulatory networks. Of particular relevance are those TFs that are expressed in small subsets of cells and thus are candidate cell type-specific regulators. One such class is the Forkhead (Fkh) family of TFs. Although the mesodermal expression patterns and developmental functions of at least 12 mammalian Fkh TFs have been characterized (Carlsson and Mahlapuu, 2002; Wijchers et al., 2006), the functions of only three of the seven Fkh genes expressed in one or more Drosophila mesodermal cell types (Grossniklaus et al., 1992; Zaffran et al., 2001; Lee and Frasch, 2004) are currently known.

In the present study, we identified three Fkh-binding sites in the enhancer of Nidogen (Ndg), a gene that is expressed at different stages and in multiple mesodermal cell types. These binding sites, which correspond to two distinct sequence specificities, were used to examine the roles of Fkh TFs in regulating various temporal and spatial patterns of mesodermal gene expression. Our results show that different tissue-specific Fkh TFs mediate distinct gene expression responses through differential use of the same binding sites in a single enhancer, and support a role for these factors in determining the unique genetic programs that characterize different subtypes of mesodermal cells.
MATERIALS AND METHODS
Identification of Fkh binding sites in the Ndg enhancer
The binding specificities of five mouse Fkh TFs, Foxa2, Foxj1, Foxj3, Foxk1 and Foxk1 (Robisky and Bulyk, 2011) were used to identify three Fkh-binding sites within a previously characterized mesodermal enhancer from the Ndg gene (Philippakis et al., 2006) (Fig. 1; supplementary material Table S1). The ability of these sites to bind relevant Drosophila Fkh TFs was subsequently confirmed by electrophoretic mobility shift assays (EMSAs).

Electrophoretic mobility shift assays
EMSAs were performed using biotinylated probes produced by the Biotin 3′ End DNA Labeling Kit (Thermo Fisher Scientific) and Bin, CHES-I-like and Jumu proteins. For Bin and CHES-I-like, GST-FKH domain fusion proteins were synthesized using the PUREExpress In Vitro Protein Synthesis Kit (NEB). For Jumu, His-tagged, full-length protein was expressed in E. coli and purified using Ni-NTA agarose resin (Invitrogen). DNA-binding reactions were carried out at room temperature for 30 minutes in a buffer containing biotinylated probes (10 fmol), 10 mM Tris (pH 7.5), 100 mM KCl, 1 mM DTT, 50 μg/ml of Poly (dl-dC), 5% glycerol and proteins. For competitive EMSAs, a 100-fold molar excess of the indicated unlabeled probes was used, which have sequences corresponding to the relevant wild-type Fkh sites, the mutated Fkh sites used in the reporters, and a non-coding sequence from the Drosophila genome lacking specific Fkh-binding sites (the non-specific competitor). Reaction products were resolved by being run on 6% non-denaturing PAGE gels, and signals were produced with the LightShift Chemiluminescent EMSA Kit (Thermo Fisher Scientific) as described in the manufacturer’s protocol.

DNA constructs and fly transformation
Ndg enhancers with mutant Fkh-binding sites were synthesized by Integrated DNA Technologies, with mutations designed to match nonbinding k-mers from published data (Robisky and Bulyk, 2011). In each case, the mutation was designed to substitute the minimum number of nucleotides and to avoid creating or altering the binding sites of other known TFs. Versions of the Ndg enhancer were cloned into the pWattH-GFP vector (Busser et al., 2012b) and microinjected into Drosophila embryos containing a specific attP site to facilitate site-specific recombination (Groth et al., 2004; Markstein et al., 2008). A P-element construct containing a β-galactosidase reporter driven by the wild-type Ndg enhancer was used as a control (Philippakis et al., 2006).

Drosophila strains and genetics
The following mutant alleles, deficiencies and transgenes were used: hid<sup>12</sup> and UAS-bin (Zaffran et al., 2001); Df(3R)Exc6157, a small deficiency that deletes jum GAL4 (Yin et al., 1997); TinD-GAL4 (Greig and Akam, 1993); and Hand-GAL4 (Han and Olson, 2005). Mutant chromosomes were maintained over the TM3, fzt-lacZ balancer.

In situ hybridization, immunohistochemistry and cell counting
Embryo fixation, probe synthesis and histochemical staining were carried out as described previously (Estrada et al., 2006). For all quantitative studies of gene expression, cells in over 100 hemisegments were counted for each genotype examined.

RNA interference assays
RNA interference assays were performed as previously described (Estrada et al., 2006). More than 15 live embryos were analyzed for each injection, and each dsRNA was injected and scored blindly.

Statistical methods
The comparisons of expression changes in cardiac cells (CCs) and pericardial cells (PCs) by mutation type are based on comparing the average number of errors (de-repressed cells) per hemisegment in each mutation group. A comparison using t-tests or analysis of variance techniques is not appropriate as the hemisegments for a given embryo are correlated in their likelihood of having errors. Bootstrap and permutation approaches (Good, 1994) were used here to address this correlation and the additional complication that the wild type showed no errors (and hence no variation) for some assays. Permutation tests were used to test for differences in errors per hemisegment between two given mutation types. Bootstrap approaches were used to determine whether non-additive interactions exist among mutation types and if the number of de-repressions per hemisegment differed between morphologically normal and abnormal hemisegments of a given mutation type.

RESULTS
Fkh binding sites in a mesodermal enhancer associated with the Ndg gene
Our previous work identified an enhancer associated with the Ndg gene that recapitulates endogenous expression in multiple mesodermal cell types where Fkh TFs are expressed, including several somatic muscle founder cells (FCs), subsets of both the pericardial cells (PCs) and cardiac cells (CCs) of the heart, and the visceral musculature (VM) (Philippakis et al., 2006; see below). Given the relative paucity of information about Fkh protein function in Drosophila, we used the known binding specificities of 5 mouse Fkh TFs (Badis et al., 2009) to detect potential Fkh-binding sites within the Ndg enhancer. The binding preferences of these mammalian Fkh TFs were previously shown to correspond to a canonical (primary) Fkh-binding motif (hereafter referred to as FkhP), the effects of which have been extensively investigated (Zaffran et al., 2001; Zaffran and Frasch, 2002; Popchenko et al., 2007; Zinzen et al., 2009), and a secondary motif (FkhS), which represents an alternate binding preference (Badis et al., 2009). We identified three Fkh-binding sites within the Ndg enhancer: Fkh1, which reflects the FkhP motif; and the adjacent and overlapping sites Fkh2 and Fkh3, which match the FkhS motif (Fig. 1A,B). Of note, sequences corresponding to both the FkhP and FkhS motifs were found at the same sites in other Drosophila species (supplementary material Table S1). Electrophoretic mobility shift assays (EMSAs) confirmed that three Drosophila mesodermal Fkh TFs bind to these sites (Fig. 1E-H). Although the binding to some of these sites is relatively weak, albeit sequence specific, we note that low-affinity binding of some TFs has previously been shown to be developmentally important (Rowan et al., 2010; Parker et al., 2011), and that actual in vivo binding affinities can be modulated by interactions with potential co-factors and collaborating TFs that are not present in in vitro assays.

To test whether Fkh TFs regulate the Ndg enhancer, we used relevant protein binding microarray data to create a series of Fkh-binding site mutations in the wild-type sequence (Fig. 1B; supplementary material Table S1). Competitive EMSAs demonstrated that each of these mutations resulted in significant loss of binding of the relevant Fkh TFs to these sites (Fig. 1E-H). The wild-type and mutant versions of the Ndg enhancer were cloned in GFP reporter vectors and independently inserted into precisely the same location on the third chromosome (Groth et al., 2004; Markstein et al., 2008). Thus, any differences in reporter
expression between the wild-type and mutant enhancer constructs is attributable to the Fkh-binding site mutations and not to local positional effects.

**Fkh regulation of Ndg expression in the visceral mesoderm**

To examine the roles of Fkh TFs in regulating the Ndg enhancer, we examined embryos that contained Ndg-GFP reporters with various Fkh site mutations and in which β-galactosidase expression driven by a Ndg WT-lacZ reporter was used as a wild-type reference to assess the activities of the mutant GFP reporters. The wild-type Ndg enhancer-reporter construct is expressed strongly in the midgut VM from stage 15 onwards (Fig. 2A–A′), which is similar to the expression of the endogenous gene (supplementary material Fig. S1D). Mutations in either the Fkh2 or Fkh3 sites did not have a significant effect on GFP reporter expression in the midgut mesoderm (Fig. 2B–C′); however, mutating both Fkh2 and Fkh3 sites simultaneously resulted in a dramatic decrease in VM expression (Fig. 2D–D′). Mutating only the Fkh-binding site also caused a significant decrease in Ndg reporter expression (Fig. 2E–E′). Finally, mutating all three Fkh sites in the same enhancer resulted in complete inactivation of the GFP reporter in the VM (Fig. 2F–F′). Taken together, these results indicate that the wild-type VM expression of Ndg requires binding of a Fkh TF to both the Fkh1 site and either the Fkh2 or the Fkh3 site.
Table S2, Fig. S2). We next assessed whether blocking the function of any of these VM-specific Fkh TFs affects expression of either the wild-type Ndg enhancer-reporter or the endogenous Ndg gene. As no loss-of-function mutations are available for either fd64A or fd96Cu, their effects were assessed by RNA interference. Embryos injected with dsRNAs corresponding to either fd64A or fd96Cu showed no reduction in Ndg WT-GFP reporter expression levels compared with the lacZ dsRNA control (supplementary material Fig. S1A-C), indicating that these Fkh genes do not regulate Ndg expression in the VM. Another Fkh TF, crocodile (supplementary material Fig. S2B’), was not considered as a candidate for regulating the late VM expression of Ndg because it is not co-expressed with Ndg in the same visceral muscle layer.

Thus, Bin remained the only candidate Fkh TF for controlling the VM activity of the Ndg enhancer, and in situ hybridization experiments demonstrated that endogenous midgut expression of Ndg is completely eliminated in embryos homozygous for the binL1 allele (supplementary material Fig. S1E). Furthermore, EMSAs showed that Bin bound specifically to all three of the wild-type Fkh motifs in vitro, and that this binding could be competed with the wild type but not with the mutated binding sites (Fig. 1E), results that correlated with the effect of mutated Fkh sites on enhancer activity. However, as loss of bin function results in the transformation of a large proportion of the VM into a somatic body wall muscle fate (Zaffran et al., 2001), it is possible that the absence of Ndg expression in bin mutants could be an indirect effect.

To further assess the potential role of Bin in regulating the Ndg enhancer, twist-GAL4 was used to overexpress Bin throughout the mesoderm. Although this manipulation causes the conversion of somatic and cardiac into visceral mesoderm (Zaffran et al., 2001), an increase in mesodermal Ndg reporter expression was induced by ectopic Bin (supplementary material Fig. S1F-I’). With this loss of bin function, this result is consistent with a direct role of Bin in regulating the Ndg enhancer, but the possibility that it is an indirect consequence of a cell fate transformation cannot be eliminated. Nevertheless, as the Ndg enhancer appears to be inactive in bin mutant embryos but is unaffected by the loss of the other VM Fkh TFs, Bin is the most likely candidate Fkh TF regulating Ndg expression in the midgut musculature. Note that this does not preclude other, non-Forkhead, TFs from also playing a role in activating the Ndg enhancer in the VM.

**Fkh regulation of Ndg expression in somatic myoblasts**

Ndg is expressed at embryonic stage 11 in a group of FCs in the ventral mesoderm of each abdominal hemisegment (Estrada et al., 2006; Philippakis et al., 2006), a pattern that is recapitulated by the wild-type Ndg enhancer-reporter (Fig. 3A-A”; supplementary material Fig. S3A-B”; Fig. S4A-B”). Neither the Ndg gene nor this GFP reporter is expressed in FCMs, cells that express the lame duck (lmd) gene and have a different developmental origin from FCs (Duan et al., 2001) (Fig. 3A-A”). Individual mutations of the Fkh1-, Fkh2- or Fkh3-binding sites in the Ndg enhancer caused no alteration in reporter expression in somatic myoblasts (data not shown). However, mutating both the Fkh2 and Fkh3 sites simultaneously, or all three Fkh sites together, resulted in decreased expression of the Ndg reporter into nearby lmd-expressing FCs without affecting enhancer activity in FCs (Fig. 3B-C”; supplementary material Figs S3, S4). These findings indicate that one or more TFs repress the Ndg enhancer in FCs by acting through either the Fkh2 or Fkh3 site.

**Fig. 2. Expression driven by the Ndg enhancer in the gut musculature is significantly reduced by mutating either the Fkh1 site or both Fkh2 and Fkh3 sites simultaneously.** (A-F) The expression of GFP reporters for the wild-type (A-A”) and mutated (B-F”) Ndg enhancers was compared at stage 16. Expression of a β-galactosidase reporter from the wild-type Ndg enhancer, Ndg WT-lacZ, was used in every embryo as a reference and an internal control. Anterior is towards the left in every panel. Mutating either the Fkh2 (B-B”) or the Fkh3 (C-C”) site alone had no significant effect on reporter expression in the gut musculature, while mutating both these sites simultaneously (D-D”) resulted in a dramatic decrease in visceral muscle expression. Mutating only the Fkh1-binding site (E-E”) also caused a significant decrease in Ndg reporter expression, while mutating all three sites simultaneously (F-F”) resulted in the complete inactivation of GFP reporter expression in the visceral muscle. Note that although Ndg expression in the heart (arrows) is visible in every embryo, it is more readily apparent for the GFP reporters, which is a consequence of: (1) GFP being expressed throughout the entire cytoplasm, as opposed to β-galactosidase, which is confined to the much smaller nuclei; (2) the plane of focus being on the gut muscle and not the heart; and (3) derepression into additional cardiac cells occurring only for the GFP reporters in which Fkh sites are mutated in B-F” (also see Fig. 4 and the main text).

Of the 17 *D. melanogaster* Fkh genes, only Checkpoint suppressor homologue (CHES-1-like) is expressed in FCs (Estrada et al., 2006; supplementary material Table S2 and Fig. S2F, Fig. S5A-A”), thus making it the only candidate for the Fkh TF repressor in this subset of mesodermal cells. Moreover, EMSAs showed that CHES-1-like bound specifically to all three of the wild-type Fkh-binding sites in vitro, and that this binding could be competed with the wild type but not with the mutated binding sites.
enhancer is also de-repressed into adjacent FCMs (arrows). Ndg from the wild-type -positive FCs. (that are adjacent to the normal Ndg simultaneously (B-B Ndg type embryos with FCMs marked by the expression of Lmd (red) at low (A-D) and high (A’-D’)) magnification. (A-A’) GFP expression driven by the wild-type Ndg enhancer (green) is limited to somatic FCs that do not express the FCM marker Lmd. (B-C’) Mutating either Fkh2 and Fkh3 sites simultaneously (B-B’) or all three Fkh sites together (C-C’) results in the de-repression of reporter expression into Lmd-expressing FCMs (arrows) that are adjacent to the normal Ndg-positive FCs. (D-D’) Similarly, in embryos homozygous for the CHES-1-like null mutation, reporter expression from the wild-type Ndg enhancer is also de-repressed into adjacent FCMs (arrows).

(Fig. 1F), results that further strengthen this hypothesis. Therefore, in order to ascertain whether CHES-1-like actually represses Ndg expression in the FCMs, we examined embryos homozygous for the CHES-1-like null mutation Df(1)CHES-1-like1. In the complete absence of CHES-1-like function, activity of the wild-type Ndg enhancer-reporter is de-repressed into Lmd-expressing FCMs (Fig. 3D’”; supplementary material Fig. S3-G’”). demonstrating that CHES-1-like is indeed the Fkh TF responsible for repressing Ndg expression in FCNs. Note, in particular, that this de-repression is a direct consequence of the absence of CHES-1-like on the Ndg enhancer; no supernumerary FCs, which could also explain the additional Ndg-expressing cells, are produced in CHES-1-like mutants (supplementary material Fig. S4E-E’).

Of note, the degree of de-repression of the Ndg-WT-GFP reporter in CHES-1-like null mutants is lower than that of the NdgFkh1+2+3-GFP or NdgFkh2+3-GFP reporters in wild-type embryos (Fig. 3; supplementary material Figs S3, S4). One plausible explanation for these observations is the existence of another repressor, which binds to at least one region overlapping the Fkh sites in the Ndg enhancer. In CHES-1-like mutants, this additional repressor could still function, resulting in a reduced level of Ndg de-repression. In addition, the de-repression caused by either mutating the Fkh sites in the Ndg enhancer or by eliminating CHES-1-like function is detected in only a small subset of FCNs, further suggesting the existence of another FCM-restricted repressor.

Fkh regulation of Ndg expression in the heart

The Drosophila heart at embryonic stage 16 consists of multiple cell types arranged in a metamerically repeated and stereotyped pattern. Each hemisegment consists of a row of six CCs representing distinct subtypes based on the expression of various marker genes. From anterior to posterior, and named after the TFs they express, there are two Seven-up-CCs (Svp-CCs), two Tinman-Ladybird-CCs (Tin-Lb-CCs) and two CCs expressing only Tin (Tin-CCs). A larger number of PCs surround the cardiac cells: four Odd-skipped-PCs (Odd-PCs) are positioned laterally, two Even-skipped-PCs (Eve-PCs) are situated dorsolaterally and a row of Tin-PCs runs immediately ventral to the CCs (Azpiazu and Frasch, 1993; Bodmer, 1993; Jagla et al., 1997; Ward and Skeath, 2000).

Mutagenesis of any one of the three Fkh-binding sites in the Ndg enhancer causes significant de-repression of GFP reporter expression from the Tin-Lb-CCs into the neighboring Svp-CCs and Tin-CCs (Fig. 4B-D”,G; supplementary material Table S3 and Fig. S6), in all of the Tin-PCs lying immediately ventral to the CCs, and in a small number (less than one cell per hemisegment, on average) of the Odd-PCs (Fig. 4A”-H”; supplementary material Table S3). As expected, mutations in multiple Fkh-binding sites also exhibited similar de-repression (Fig. 4E-H; supplementary material Table S3). Activity of each mutant enhancer in the Tin-PCs was entirely unaffected (supplementary material Fig. S7).

Only two Drosophila Fkh genes, CHES-1-like and jumu, are expressed in the cardiac mesoderm (supplementary material Table S2 and Figs S2, S5), and EMSAs showed that while CHES-1-like bound to all three wild-type Fkh sites in the Ndg enhancer, Jumu bound specifically to only the wild-type Fkh2 site in vitro (Fig. 1F,G). We therefore considered both CHES-1-like and Jumu as candidates for repressing Ndg expression in the heart. Embryos homozygous for the CHES-1-like null mutation, Df(1)CHES-1-like1, homozygous for the jumu null deficiency, Df(3R)Exel6157, or bearing the jumu1-12 hypomorphic allele in trans to Df(3R)Exel6157, all exhibited significant de-repression of the wild-type Ndg enhancer-reporter in both CCs and Odd-PCs (Fig. 5A-D”; supplementary material Table S3 and Fig. S8), precisely as observed for versions of the Ndg enhancer that contain mutations in Fkh-binding sites. The convergence of results for these cis and trans experiments suggests that CHES-1-like and Jumu both repress the Ndg enhancer in all heart cells, excluding the Tin-Lb-CCs and ventral Tin-PCs.
Loss-of-function mutations in either jumu or CHES-1-like also result in the generation of morphologically abnormal hemisegments owing to defects in the specification of cardiac cell fates and numbers (S.M.A., T.R.T., B.W.B., M. T. Nolte, N.J., S. S. Gisselbrecht, N. M. Rusan and A.M.M., unpublished; Fig. 5B-B/H11630, D-D/H11630). As not all hemisegments in homozygous mutant embryos exhibit this latter phenotype, we assessed whether there is any correlation between the de-repression of a specific gene and the morphological defects associated with mutations in jumu or CHES-1-like. Either no or barely significant differences were observed in the degree of de-repression in either CCs or Odd-PCs between morphologically normal and abnormal hemisegments for mutations in either gene (\(P=0.02\) for CCs and \(P=0.28\) for PCs in jumu mutants; \(P=0.11\) for CCs and \(P=0.08\) for PCs in CHES-1-like mutants). These results suggest that Ndg and the additional targets of these two Fkh TFs that are involved in specifying cardiac cell numbers and fates respond independently to the loss of jumu and CHES-1-like functions. We also determined that the de-repression of Ndg into neighboring CCs was a direct consequence of the absence of either Jumu or CHES-1-like TFs as expression of Ndg in additional CCs was not correlated with an expansion of Tin-Lb-CCs in jumu or CHES-1-like mutants (supplementary material Fig. S6).

We assayed the effects of jumu and CHES-1-like on Ndg enhancer activity at stage 16 owing to the perdurance of GFP in the regular arrangement of CCs and PCs, which afforded ease of quantitation. However, the regulatory effects of these TFs are expected to occur much earlier, that is, in the cardiac mesoderm during stage 11. Thus, we assessed whether the observed cis and trans effects of Fkh regulation of Ndg actually initiate at the earlier stage by double labeling appropriate stage 11 embryos for GFP and endogenous Mef2 expression. These experiments revealed that there is a significant de-repression of the NdgWT reporter in jumu and CHES-1-like mutants, and of the mutated enhancer-reporters in otherwise wild-type embryos, confirming that the repression of Ndg expression in the heart by these two Fkh TFs does occur when they are initially expressed in the cardiac mesoderm (supplementary material Fig. S9).

To confirm that Jumu functions as a transcriptional repressor of Ndg in the heart, we overexpressed Jumu protein by crossing UAS-jumu to both TinD-GAL4 and Hand-GAL4 drivers, which caused a dramatic reduction of Ndg reporter expression in the Tin-Lb-CCs (Fig. 5E-E/H11630; supplementary material Table S3 and Fig. S10) and in the ventral-most Tin-PCs (data not shown). In addition, if the repressive activity of Jumu is mediated by interaction of this TF with the Fkh sites in the Ndg enhancer, then mutating these binding sites should block the effect of jumu overexpression. We tested this hypothesis by examining the expression of the NdgFkh1+2+3 reporter in embryos in which Jumu was overexpressed under the control of both TinD-GAL4 and Hand-GAL4. NdgFkh1+2+3 was expressed in normal and additional CCs and Odd-PCs in the presence of ectopic Jumu (Fig. 5F-F/H11630; supplementary material Table S3), indicating that the repressive effect of Jumu is blocked by mutations that prevent Fkh TF binding. These results suggest that Jumu acts through Fkh-binding sites to repress Ndg expression in the heart.
Fkh TF binding sites are significantly overrepresented in combination with known co-regulatory heart TF binding sites in putative cardiac-specific enhancers

The roles of Jumu and CHES-1-like in regulating Ndg expression in both CCs and PCs raise the question of whether these two Fkh TFs also control the expression of other genes involved in cardiac development. To address this issue, we used a computational approach to assess whether Fkh-binding sites are enriched in putative enhancers associated with other heart genes (Philippakis et al., 2006; Warner et al., 2008). 

Drosophila cardiac development involves contributions from multiple regulators, including the tissue-specific TFs Twist (Twi) and Tin; and Pointed (Pnt), T-cell factor (Tcf) and Mothers against Dpp (Mad), which are activated by the receptor tyrosine kinase (RTK)/Ras/MAPK, Wingless and Decapentaplegic pathways, respectively (Azpiazu and Frasch, 1993; Bodmer, 1993; Staehling-Hampton et al., 1994; Frasch, 1995; Carmena et al., 1998; Halfon et al., 2000; Halfon et al., 2002). If Jumu and CHES-1-like act in concert with one or more of these TFs to regulate cardiac-specific gene expression, then a significant fraction of heart genes – although not necessarily all – would be expected to have enhancers containing Fkh motifs associated with binding sites for all or subsets of the aforementioned TFs. We tested this possibility by using the Lever algorithm (Warner et al., 2008), which detects significant overrepresentations of given combinations of evolutionarily conserved TF-binding sites within putative cis-regulatory modules in the noncoding regions of defined lists of genes.

This approach revealed that both Fkh primary and secondary motifs are enriched along with multiple combinations of subsets of Tcf-, Mad-, Ets-, Twi- and Tin-binding sequences within putative enhancers associated with the noncoding regions of CC and PC genes (supplementary material Table S4). Of note, this degree of enrichment is seen only with authentic FkhP and FkhS motifs for genes expressed in the heart, but not with motifs for which the Fkh-binding sequences have been shuffled as a control. By contrast, no enrichment is observed with the actual Fkh site motifs when a collection of random genes is used as the foreground (Fig. 6B). Furthermore, three CC enhancers, including the Ndg enhancer used to test for Fkh motif function in the present study, conform to the 7-way AND combination of motifs that includes those for the five established cardiac TFs and both Fkh primary and secondary sequences (Fig. 6C; supplementary material Table S4 and Fig. S11). Although not all of these binding sites in the Ndg enhancer have been functionally tested, mutating either the Ets site or the Tin site eliminates enhancer activity in the heart (Busser et al., 2012a) (supplementary material Fig. S12).

A similar, although less pronounced result was obtained for PC genes (supplementary material Table S4). Although clearly not all CC and PC genes contain candidate enhancers that
conform to the *Ndg* regulatory model, the present results suggest that Fkh TFs are potentially regulating large numbers of heart genes.

**DISCUSSION**

In this study, we have characterized the regulatory functions of multiple Fkh TFs and their binding sites in the control of gene expression in different mesodermal cell types in the *Drosophila* embryo. Specifically, we identified three Fkh-binding sites in a minimal enhancer of the *Ndg* gene, which mediate the effects of different cell type-specific Fkh TFs and are used in various combinations to regulate enhancer activity in a subset of somatic myoblasts, in differentiated visceral muscle and in progenitors of both the cardiac and pericardial cells of the heart (Fig. 7).

**Differential regulation of mesodermal gene expression by tissue-specific Fkh TFs**

To drive expression in the visceral mesoderm, the Fkh1 site in the *Ndg* enhancer is required in concert with either the Fkh2 or Fkh3 site (Fig. 7A,B). The trans-acting factor responsible for this activity of the *Ndg* enhancer is likely to be Bin because: (1) Bin bound to all three Fkh sites in vitro; (2) among the three candidate Fkh genes with appropriate VM expression, eliminating the function of only *bin* resulted in a significant reduction of *Ndg* expression in this tissue; and (3) Bin overexpression in the mesoderm was associated with *Ndg* enhancer activity in additional mesodermal cells. There are multiple precedents for Bin activating the expression of other VM genes (Zaffran et al., 2001; Zaffran and Frasch, 2002; Jakobsen et al., 2007; Popichenko et al., 2007). Moreover, chromatin immunoprecipitation assays show that Bin binds in vivo to the *Ndg* enhancer throughout embryonic stages 14 to 15, precisely when it would be expected to regulate this element in the visceral musculature (Jakobsen et al., 2007; Zinzen et al., 2009).

Somatic muscles in *Drosophila* are formed by the sequential fusion of individual muscle FCs with multiple FCMs. Both the endogenous *Ndg* gene and the reporter driven by the minimal enhancer used in this study are expressed in a subset of FCs, but not in any FCMs. Mutating all three Fkh-binding sites had no effect on *Ndg* expression in FCMs, suggesting that Fkh factors do not play a role either in activating *Ndg* reporter expression in certain FCs, or in repressing it in other FCs. By contrast, binding of the FCM-expressed Fkh TF CHES-1-like to the Fkh2 or Fkh3 sites mediated repression of *Ndg* expression in FCMs (Fig. 7C). The design of the experiment prevented us from determining unambiguously whether this repression also required CHES-1-like binding to the Fkh1 site. CHES-1-like binds to all three sites, whereas Jumplike binds to the Fkh1 site to repress *Ndg* reporter expression in CCs and Odd-PCs.

**DISCUSSION**

In this study, we have characterized the regulatory functions of multiple Fkh TFs and their binding sites in the control of gene expression in different mesodermal cell types in the *Drosophila* embryo. Specifically, we identified three Fkh-binding sites in a minimal enhancer of the *Ndg* gene, which mediate the effects of different cell type-specific Fkh TFs and are used in various combinations to regulate enhancer activity in a subset of somatic myoblasts, in differentiated visceral muscle and in progenitors of both the cardiac and pericardial cells of the heart (Fig. 7).

**Differential regulation of mesodermal gene expression by tissue-specific Fkh TFs**

To drive expression in the visceral mesoderm, the Fkh1 site in the *Ndg* enhancer is required in concert with either the Fkh2 or Fkh3 site (Fig. 7A,B). The trans-acting factor responsible for this activity of the *Ndg* enhancer is likely to be Bin because: (1) Bin bound to all three Fkh sites in vitro; (2) among the three candidate Fkh genes with appropriate VM expression, eliminating the function of only *bin* resulted in a significant reduction of *Ndg* expression in this tissue; and (3) Bin overexpression in the mesoderm was associated with *Ndg* enhancer activity in additional mesodermal cells. There are multiple precedents for Bin activating the expression of other VM genes (Zaffran et al., 2001; Zaffran and Frasch, 2002; Jakobsen et al., 2007; Popichenko et al., 2007). Moreover, chromatin immunoprecipitation assays show that Bin binds in vivo to the *Ndg* enhancer throughout embryonic stages 14 to 15, precisely when it would be expected to regulate this element in the visceral musculature (Jakobsen et al., 2007; Zinzen et al., 2009).

Somatic muscles in *Drosophila* are formed by the sequential fusion of individual muscle FCs with multiple FCMs. Both the endogenous *Ndg* gene and the reporter driven by the minimal enhancer used in this study are expressed in a subset of FCs, but not in any FCMs. Mutating all three Fkh-binding sites had no effect on *Ndg* expression in FCMs, suggesting that Fkh factors do not play a role either in activating *Ndg* reporter expression in certain FCs, or in repressing it in other FCs. By contrast, binding of the FCM-expressed Fkh TF CHES-1-like to the Fkh2 or Fkh3 sites mediated repression of *Ndg* expression in FCMs (Fig. 7C). The design of the experiment prevented us from determining unambiguously whether this repression also required CHES-1-like binding to the Fkh1 site. These results reveal a mechanism for regulating somatic myoblast gene expression that has not been previously recognized. Prior studies have focused on the contributions of signal-activated,
tissue-specific and FC identity TFs in specifying the unique genetic programs of this class of myoblast (Halfon et al., 2000; Busser et al., 2008). Similarly, TFs such as Lmd are known to be responsible for activating FCM-specific genes (Duan et al., 2001; Ruiz-Gomez et al., 2002). However, we have now uncovered a novel mode of regulation in which FC genes are excluded from FCMs by an FCM-restricted repressor, in this case in the form of a Fkh domain protein. CHES-1-like is unlikely to be the only repressor playing such a role, as the de-repression in CHES-1-like mutants is limited to only a subset of the FCMs and is weaker than that seen for the Ndg enhancer with mutated Fkh sites. Although not verified functionally, it is possible that Lmd could play a similar repressive role in FCMs as a chromatin immunoprecipitation study found that this TF is bound extensively to FC genes (Cunha et al., 2010). However, given the widespread expression of CHES-1-like in FCMs, we anticipate that many other FC genes will also be repressed by this Fkh domain TF.

Finally, in the heart, we show that CHES-1-like and Jumu repress Ndg expression in Odd-PCs and in all CCs other than Tin-Lb-CCs. Repression in these cardiac cell types is mediated by binding of CHES-1-like to all three of the Fkh sites in the Ndg enhancer, and of Jumu to at least the Fkh2 site (Fig. 7A,D,E).

Use of the same enhancer to respond to different tissue-specific Fkh TFs

A common occurrence in development is the repeated function of the same gene in multiple biological contexts and regulatory processes, which requires that the gene be expressed in distinct spatial and temporal domains. Such expression patterns are often generated by differential transcription mediated by multiple enhancers, each with its own arrangement of TF-binding sites and associated activities (Davidson, 2006). A notable exception is the case of genes regulated by Hox TFs, where different family members exhibit similar binding sequence specificity but exert differential effects on the same target genes (Hueber and Lohmann, 2008; Mann et al., 2009).

The results of the present study identify another class of TFs, the Fkh proteins, which exhibit a similar role in the Drosophila embryonic mesoderm. Specifically, we have shown that various cell-specific members of the Fkh TF family associate with the same binding sites within a single enhancer, thereby regulating the different spatiotemporal expression patterns of the associated target gene. Furthermore, we have shown that the distinct tissue-specific gene expression responses to these Fkh TFs are mediated by the TFs binding to different combinations of Fkh primary and secondary motifs that are represented by these sites. Thus, it was interesting to see that in several Drosophila species, where the Fkh1 site (which is the only site corresponding to the Fkh primary motif in D. melanogaster) is absent, its role may be compensated for by the overlapping Fkh2 and Fkh3 sites (which match only the secondary motif in D. melanogaster), which correspond to both Fkh primary and secondary motifs in these species (supplementary material Table S1). Similar evolutionary shuffling of motifs has been described previously (Ludwig et al., 2000; Hare et al., 2008).

Finally, we used a computational approach to attempt to generalize the potential involvement of the two classes of Fkh sites in cardiac gene regulation. Specifically, within putative enhancers in the noncoding regions of heart-expressed genes, we observed a statistically significant overrepresentation of combinations of binding sites for known cardiogen FTFs along with primary and secondary Fkh motifs. These observations are in agreement with previous studies that have documented an inability of a single consensus binding site to explain all aspects of in vivo TF binding (Ji et al., 2006; Rabinovich et al., 2008; Cunha et al., 2010). In addition, we have recently shown that the regulatory specificity of a myoblast homeodomain TF is mediated by sequences preferentially bound by that particular homeodomain and not by other related family members (Busser et al., 2012b). In light of these findings, it will be interesting to determine whether other Fkh TFs and members of other TF families mediate differential gene expression responses by acting through distinct sequence motifs.

Acknowledgements

We thank H. Jäckle, A. Hofmann, A. Han, H. T. Nguyen, B. Paterson, J. B. Skeath, M. Frasch, and the Bloomington Stock Center for fly lines and reagents, and A. Cohen and C. Sonnenbrot for technical assistance. Stephen Gisselbrecht provided valuable comments throughout the course of these experiments.

Funding

This work was supported by the National Heart, Lung, and Blood Institute (NHLBI) Division of Intramural Research (A.M.M.), by the National Institutes of Health (NHL) (R01 HG005287-01A1 to M.L.B.), by an American Heart Association Predoctoral Fellowship (A.A.) and by an American Heart Association Postdoctoral Fellowship (S.M.A.). Deposited in PMC for immediate release.

Competing interests statement

The authors declare no competing financial interests.

Supplementary material

Supplementary material available online at http://dev.biologists.org/lookup/doi/10.1242/dev.069005/-/DC1

References


